Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Anal Cancer. According to GlobalData, Phase II drugs for Anal Cancer have a 19% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vobramitamab duocarmazine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vobramitamab duocarmazine overview

Vobramitamab duocarmazine (MGC-018) is under development for the treatment of solid tumors such as ovarian cancer, small-cell lung cancer, anal cancer, prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), pancreatic cancer, hepatocellular carcinoma, renal cell carcinoma, castration-resistant prostate cancer (CRPC), head and neck squamous cell carcinoma, squamous non-small cell lung cancer, and ocular melanoma. It is administered through intravenous route. The therapeutic candidate is an antibody-drug conjugate duocarmycin-based linker payload which acts by targeting cells expressing CD276 antigen (B7-H3). 
The therapeutic candidate as under development for the treatment of triple negative breast cancer, non-small cell lung cancer, head and neck squamous cell carcinoma and metastatic uveal melanoma.

MacroGenics overview

MacroGenics is a biopharmaceutical company which focuses on the development and delivery of novel antibody-based therapeutics for the treatment of cancer, infectious diseases and autoimmune disorders. Its product pipeline includes candidates for the treatment of solid tumors, HIV, breast and gastroesophageal cancers, type 1 diabetes, DART product candidates for the treatment of acute myeloid leukemia and myelodysplastic syndrome; and b-cell malignancies. The company’s product candidates are based on proprietary technology platforms, namely, cancer stem cell platform, dual-affinity re-targeting (or DART) and Trident platform, and FC optimization platform. It works in collaboration with various pharmaceutical and biotechnology companies to leverage its technology platforms and protein engineering capabilities for development. MacroGenics is headquartered in Rockville, Maryland, the US.

For a complete picture of Vobramitamab duocarmazine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.